Gene · 4507
Papers2,281
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
221 to 240 of 2,281
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrative analysis of polyamine metabolism-related genes in gliomas: implications for prognosis and therapy. | Front Oncol | 2025 | 40761256 | PubTator, text mining | PubMed |
| Mitophagy's impacts on cancer and neurodegenerative diseases: implications for future therapies. | J Hematol Oncol | 2025 | 40750884 | PubTator, text mining | PubMed |
| A systematic literature review of MTAP deletions in solid and hematologic Cancers. | Cancer Treat Res Commun | 2025 | 40729867 | PubTator, text mining | PubMed |
| CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. | Cancer Res | 2025 | 40694540 | PubTator, text mining | PubMed |
| Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. | Cancer Res | 2025 | 40694535 | PubTator, text mining | PubMed |
| Genetic mutations in recurrent and/or metastatic nasopharyngeal carcinoma - an analysis of the Japanese national genomic profiling database. | Otolaryngol Pol | 2025 | 40678837 | PubTator, text mining | PubMed |
| Discovery of Novel MTA-Cooperative PRMT5 Inhibitors with a 2,3-Dihydro‑1H‑imidazo[1,2‑b]pyrazole Scaffold. | ACS Med Chem Lett | 2025 | 40666447 | PubTator, text mining | PubMed |
| MTAP deficiency is highly homogeneous in advanced, muscle-invasive urothelial carcinoma of the urinary bladder. | Sci Rep | 2025 | 40664803 | PubTator, text mining | PubMed |
| The catalytic efficiency of METTL16 affects cellular processes by governing the intracellular S-adenosylmethionine setpoint. | Cell Rep | 2025 | 40644296 | PubTator, text mining | PubMed |
| MTAP and p16 as immunohistochemical surrogates of CDKN2A/B homozygous deletion in central nervous system tumors: A multicentre Italian experience. | Ann Diagn Pathol | 2025 | 40638988 | PubTator, text mining | PubMed |
| Prognostic Role of MTAP Loss in Cholangiocarcinoma. | JCO Precis Oncol | 2025 | 40638878 | PubTator, text mining | PubMed |
| CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial. | ESMO Open | 2025 | 40627883 | PubTator, text mining | PubMed |
| Genomic Landscape of Non-Squamous Non-Small Cell Lung Cancer in a Southern Brazilian Population: High PDL-1 Expression and Enrichment of EGFR and TP53 Mutations. | J Interferon Cytokine Res | 2025 | 40626853 | PubTator, text mining | PubMed |
| Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma. | Mol Cancer Ther | 2025 | 40621788 | PubTator, text mining | PubMed |
| Polyamines at the crossroad between cell metabolism and epigenetic regulation in acute leukemias. | Cell Death Discov | 2025 | 40603833 | PubTator, text mining | PubMed |
| A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer. | J Clin Invest | 2025 | 40590221 | PubTator, text mining | PubMed |
| Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop. | J Clin Invest | 2025 | 40590219 | PubTator, text mining | PubMed |
| Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. | J Thorac Oncol | 2025 | 40578509 | PubTator, text mining | PubMed |
| Loss of MTAP expression is not an accurate surrogate for CDKN2A homozygous deletions in peritoneal mesothelioma. | Histopathology | 2025 | 40566743 | PubTator, text mining | PubMed |
| Prognostic role of high MTAP expression is reversed by the ERG status in prostate cancer treated by radical prostatectomy. | Neoplasia | 2025 | 40554389 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4507/papers?page=12